156 related articles for article (PubMed ID: 38128532)
1. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis.
Moldovan N; van der Pol Y; van den Ende T; Boers D; Verkuijlen S; Creemers A; Ramaker J; Vu T; Bootsma S; Lenos KJ; Vermeulen L; Fransen MF; Pegtel M; Bahce I; van Laarhoven H; Mouliere F
Cell Rep Med; 2024 Jan; 5(1):101349. PubMed ID: 38128532
[TBL] [Abstract][Full Text] [Related]
2. Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids.
Kim J; Hong SP; Lee S; Lee W; Lee D; Kim R; Park YJ; Moon S; Park K; Cha B; Kim JI
Hum Genomics; 2023 Oct; 17(1):96. PubMed ID: 37898819
[TBL] [Abstract][Full Text] [Related]
3. Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing.
van der Pol Y; Tantyo NA; Evander N; Hentschel AE; Wever BM; Ramaker J; Bootsma S; Fransen MF; Lenos KJ; Vermeulen L; Schneiders FL; Bahce I; Nieuwenhuijzen JA; Steenbergen RD; Pegtel DM; Moldovan N; Mouliere F
EMBO Mol Med; 2023 Dec; 15(12):e17282. PubMed ID: 37942753
[TBL] [Abstract][Full Text] [Related]
4. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
Wang S; Meng F; Li M; Bao H; Chen X; Zhu M; Liu R; Xu X; Yang S; Wu X; Shao Y; Xu L; Yin R
Am J Respir Crit Care Med; 2023 May; 207(9):1203-1213. PubMed ID: 36346614
[No Abstract] [Full Text] [Related]
5. Ultra-short cell-free DNA fragments enhance cancer early detection in a multi-analyte blood test combining mutation, protein and fragmentomics.
Wang F; Li X; Li M; Liu W; Lu L; Li Y; Chen X; Yang S; Liu T; Cheng W; Weng L; Wang H; Lu D; Yao Q; Wang Y; Wu J; Wittkop T; Faham M; Zhou H; Hu H; Jin H; Hu Z; Ma D; Cheng X
Clin Chem Lab Med; 2024 Jan; 62(1):168-177. PubMed ID: 37678194
[TBL] [Abstract][Full Text] [Related]
6. Predicting tumour content of liquid biopsies from cell-free DNA.
Cardner M; Marass F; Gedvilaite E; Yang JL; Tsui DWY; Beerenwinkel N
BMC Bioinformatics; 2023 Sep; 24(1):368. PubMed ID: 37777714
[TBL] [Abstract][Full Text] [Related]
7. Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas.
Meriranta L; Pitkänen E; Leppä S
Semin Hematol; 2023 Jul; 60(3):132-141. PubMed ID: 37455222
[TBL] [Abstract][Full Text] [Related]
8. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
[TBL] [Abstract][Full Text] [Related]
9. Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma.
Ma X; Chen Y; Tang W; Bao H; Mo S; Liu R; Wu S; Bao H; Li Y; Zhang L; Wu X; Cai S; Shao Y; Liu F; Peng J
J Hematol Oncol; 2021 Oct; 14(1):175. PubMed ID: 34702327
[TBL] [Abstract][Full Text] [Related]
10. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
Guo W; Chen X; Liu R; Liang N; Ma Q; Bao H; Xu X; Wu X; Yang S; Shao Y; Tan F; Xue Q; Gao S; He J
EBioMedicine; 2022 Jul; 81():104131. PubMed ID: 35780566
[TBL] [Abstract][Full Text] [Related]
11. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.
Ge G; Peng D; Guan B; Zhou Y; Gong Y; Shi Y; Hao X; Xu Z; Qi J; Lu H; Zhang X; Zhan Y; Li Y; Wu Y; Ding G; Shen Q; He Q; Li X; Zhou L; Ci W
Clin Chem; 2020 Jan; 66(1):188-198. PubMed ID: 31811000
[TBL] [Abstract][Full Text] [Related]
12. Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection.
Bao H; Wang Z; Ma X; Guo W; Zhang X; Tang W; Chen X; Wang X; Chen Y; Mo S; Liang N; Ma Q; Wu S; Xu X; Chang S; Wei Y; Zhang X; Bao H; Liu R; Yang S; Jiang Y; Wu X; Li Y; Zhang L; Tan F; Xue Q; Liu F; Cai S; Gao S; Peng J; Zhou J; Shao Y
Mol Cancer; 2022 Jun; 21(1):129. PubMed ID: 35690859
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Preanalytical and Physiological Variables on Cell-Free DNA Fragmentation.
van der Pol Y; Moldovan N; Verkuijlen S; Ramaker J; Boers D; Onstenk W; de Rooij J; Bahce I; Pegtel DM; Mouliere F
Clin Chem; 2022 Jun; 68(6):803-813. PubMed ID: 35292813
[TBL] [Abstract][Full Text] [Related]
14. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.
Helzer KT; Sharifi MN; Sperger JM; Shi Y; Annala M; Bootsma ML; Reese SR; Taylor A; Kaufmann KR; Krause HK; Schehr JL; Sethakorn N; Kosoff D; Kyriakopoulos C; Burkard ME; Rydzewski NR; Yu M; Harari PM; Bassetti M; Blitzer G; Floberg J; Sjöström M; Quigley DA; Dehm SM; Armstrong AJ; Beltran H; McKay RR; Feng FY; O'Regan R; Wisinski KB; Emamekhoo H; Wyatt AW; Lang JM; Zhao SG
Ann Oncol; 2023 Sep; 34(9):813-825. PubMed ID: 37330052
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic analysis of cell-free DNA by fragmentomic profiling.
Zhou Q; Kang G; Jiang P; Qiao R; Lam WKJ; Yu SCY; Ma ML; Ji L; Cheng SH; Gai W; Peng W; Shang H; Chan RWY; Chan SL; Wong GLH; Hiraki LT; Volpi S; Wong VWS; Wong J; Chiu RWK; Chan KCA; Lo YMD
Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2209852119. PubMed ID: 36288287
[TBL] [Abstract][Full Text] [Related]
16. Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.
Jin C; Liu X; Zheng W; Su L; Liu Y; Guo X; Gu X; Li H; Xu B; Wang G; Yu J; Zhang Q; Bao D; Wan S; Xu F; Lai X; Liu J; Xing J
Mol Oncol; 2021 Sep; 15(9):2377-2389. PubMed ID: 34133846
[TBL] [Abstract][Full Text] [Related]
17. Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics.
Shi X; Guo S; Duan Q; Zhang W; Gao S; Jing W; Jiang G; Kong X; Li P; Li Y; Teng C; Xu X; Chen S; Nian B; Li Z; Zhong C; Yang X; Zhu G; Du Y; Zhang D; Jin G
J Exp Clin Cancer Res; 2024 May; 43(1):145. PubMed ID: 38750539
[TBL] [Abstract][Full Text] [Related]
18. A method for early diagnosis of lung cancer from tumor originated DNA fragments using plasma cfDNA methylome and fragmentome profiles.
Kim YJ; Jeon H; Jeon S; Lee SH; Kim C; Ahn JH; Um H; Woo YJ; Jeong SH; Kim Y; Park HY; Oh HJ; Cho HJ; Bae JH; Kim JH; An S; Kang SB; Jho S; Biro O; Kis D; Kim BC; Kim Y; Kim JH; Kim BC; Bhak J; Oh IJ
Mol Cell Probes; 2022 Dec; 66():101873. PubMed ID: 36379302
[TBL] [Abstract][Full Text] [Related]
19. Testing the generalizability of cfDNA fragmentomic features across different studies for cancer early detection.
Su S; Xuan Y; Fan X; Bao H; Tang H; Lv X; Ren W; Chen F; Shao Y; Wang T; Wang L
Genomics; 2023 Jul; 115(4):110662. PubMed ID: 37270068
[TBL] [Abstract][Full Text] [Related]
20. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Chu C; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Chan JM; Friedlander T; Wyatt AW; Aggarwal R; Paris PL; Carroll PR; Feng F; Witte JS
Sci Rep; 2021 Mar; 11(1):5040. PubMed ID: 33658587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]